Category - Developments

Developments

Zucara Therapeutics in $21-million Series A funding led by Perceptive Xontogeny

Closely held Zucara Therapeutics closed a $21-million Series A financing led by the Perceptive Xontogeny Venture (PXV) Fund. Proceeds will be used for Phase 1 and Phase 2 clinical trials of ZT-01, Zucara’s first-in...

March 31, 2020

Developments

Kleo Pharma in COVID-19 research pact with Green Cross LabCell

Closely held Kleo Pharmaceuticals entered into a research collaboration with South Korea-based Green Cross LabCell, a pioneer in the next generation of allogeneic, or “off-the-shelf” natural killer cell...

March 31, 2020

Developments

Kasraeian Urology treats first Jacksonville patient with Profound’s TULSA-PRO

Dr. Ali Kasraeian of the renowned Kasraeian Urology in Jacksonville, FL, in partnership with Vituro Health, treated their first patient with Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO medical device for...

March 27, 2020

Developments

iBio supporting AzarGen’s development of plant-made rituximab

iBio (NYSE AMERICAN:IBIO) will manufacture and characterize additional supplies of plant-made rituximab for South Africa’s AzarGen, enabling preclinical studies to compare plant-made rituximab to the original molecule...

March 26, 2020

Developments

Profound Medical’s TULSA-PRO now available at Georgia’s renowned Busch Center

Georgia’s renowned Busch Center is now offering Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO procedure to treat unhealthy prostate tissue. The technology, which was cleared by the FDA in August 2019, provides...

March 26, 2020

Developments

iBio begins immunization studies of COVID-19 vaccine candidates

iBio (NYSE AMERICAN:IBIO) commenced immunization studies for its SARS-CoV-2 virus-like particle (VLP) program, IBIO-200, at Texas A&M University System laboratories. The company used its plant-based FastPharming...

March 26, 2020

Developments

Obalon hires Canaccord Genuity to explore financial and strategic alternatives

The board of Obalon Therapeutics (NASDAQ:OBLN) decided to explore potential financial and strategic alternatives intended to enhance stockholder value and has retained Canaccord Genuity as its financial advisor. The...

March 25, 2020

Developments

Prevail Therapeutics gets FDA fast track designation for frontotemporal dementia gene therapy

Prevail Therapeutics (NASDAQ:PRVL) received FDA fast track designation for PR006, a gene therapy candidate designed to slow the progression of frontotemporal dementia with a GRN mutation. Frontotemporal dementia is the...

March 24, 2020

Developments

Novavax ’ NanoFlu hits all primary, secondary endpoints in Phase 3 trial

Novavax (NASDAQ:NVAX) posted positive top-line results of its Phase 3 clinical trial of NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with its Matrix-M adjuvant, in adults aged 65 and older...

March 24, 2020

Developments

iBio Joins the Alliance for Biosecurity

iBio (NYSE AMERICAN:IBIO) joined the Alliance for Biosecurity, a coalition of biopharmaceutical companies, along with laboratory and academic partners, that promote a strong public-private partnership in order to ensure...

March 20, 2020

Category - Developments

Zucara Therapeutics in $21-million Series A funding led by Perceptive Xontogeny

Kleo Pharma in COVID-19 research pact with Green Cross LabCell

Kasraeian Urology treats first Jacksonville patient with Profound’s TULSA-PRO

iBio supporting AzarGen’s development of plant-made rituximab

Profound Medical’s TULSA-PRO now available at Georgia’s renowned Busch Center

iBio begins immunization studies of COVID-19 vaccine candidates

Obalon hires Canaccord Genuity to explore financial and strategic alternatives

Prevail Therapeutics gets FDA fast track designation for frontotemporal dementia gene therapy

Novavax ’ NanoFlu hits all primary, secondary endpoints in Phase 3 trial

iBio Joins the Alliance for Biosecurity

General

More